Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-Dotatate in first-line G2/G3 GEP-NET
NCT05894486Phase 2Not yet recruiting
- Sponsor
- Peking University
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Peking University. Primary endpoint: Objective Response Rate at 2 years. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT05894486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894486.